ClostraBio, a biotechnology company developing next-generation probiotics to transform gut health, today announced several major milestones: the commercial launch of its first product in partnership with Designs for Health (DFH), the start of a human clinical study evaluating its lead probiotic strain Anaerostipes caccae CLB101™, and its upcoming participation in SupplySide Global.

The company’s debut product featuring CLB101™ has launched through Designs for Health (DFH), a leader in science-backed nutritional supplements distributed through the healthcare practitioner channel. The partnership underscores ClostraBio’s commitment to working with organizations that share its dedication to rigorous scientific validation and education in the practitioner space.

“We are thrilled to partner with Designs for Health to introduce CLB101™ to the market,” said Ritu Shah, CEO of ClostraBio. “Our organizations share a deep commitment to scientific integrity and the advancement of evidence-based products. This alignment is precisely why we chose Designs for Health as our first commercial partner.”

ClostraBio has initiated a 48-subject clinical study evaluating Anaerostipes caccae CLB101™. The trial is designed to confirm the safety and tolerability of the company’s next-generation probiotic, with exploratory endpoints regarding its potential to support gut health and intestinal barrier integrity. The study is enrolling quickly, demonstrating the unmet need for new dietary supplements that support gut health, and immense market interest in next-generation probiotics.

“With a hypothesis-driven approach to understanding Anaerostipes caccae CLB101™’s impact on gut barrier function as well as the consumer experience, this clinical study reaffirms ClostraBio’s dedication to redefining the notion of ‘healthy’,” said Brian Meehan, CSO of ClostraBio.

In order to effectively promote these two milestones and others, ClostraBio will attend SupplySide Global from October 27-30, where the team will share its progress, connect with partners, and advocate for science-driven innovation across the probiotics industry. Additionally, Ritu Shah was selected as a SupplySide Global advocate in 2025 where she was featured in a video to discuss the importance of the event. You can view the full event video here.

About ClostraBio: ClostraBio is leveraging a science driven, multi-pronged approach to address conditions of the lower gut, using novel biotechnology to harness natural pathways. The Company is developing a next-generation probiotic that produces butyrate in the lower gut to impact intestinal barrier function and promote gut health, as well as a novel polymeric prodrug platform designed to deliver small molecules to the lower gut. ClostraBio was spun out of the University of Chicago and is incubated at Portal Innovations.

About Anaerostipes caccae CLB101™: A next-generation probiotic strain isolated from healthy humans, CLB101™ is unique and highly differentiated from legacy probiotics in that as a strict anaerobe, it has capacity to directly produce butyrate to impact gut barrier integrity, immunity and microbiome balance*. CLB101™ has achieved self-affirmed GRAS status and is currently marketed in the US as a dietary supplement. https://clb101probiotic.com/

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251023058714/en/